Immunotoxins for the treatment of B-cell lymphomas

Molecular Medicine

Volumn 3, Issue 7, 1997, Pages 420-427

  Ghetie, Maria Ana ^a   Ghetie, Victor ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN;

ANIMAL TISSUE; B CELL LYMPHOMA; CANCER GRADING; CYTOTOXICITY; DRUG EFFICACY; HEMATOLOGIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY;

EID: 0030825191     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401689     Document Type: Review

References (43)

1. Harris NL, Jaffe ES, Stein H, et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392.
2. Rosenberg SA. (1994) Classification of lymphoid neoplasms. Blood 84: 1359-1363.
3. Hiddemann W, Longo DL, Coiffier B, et al. (1996) Lymphoma classification - The gap between biology and clinical management is closing. Blood 88: 4085-4089.
4. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA. (1991) An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res. 51: 6236-6242.
5. Thorpe PE, Detre SI, Foxwell BMJ, et al. (1985) Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem. 147: 197-206.
6. Thorpe PE, Wallace PM, Knowles PP, et al. (1988) Improved anti-tumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res. 48: 6396-6403.
7. Ghetie M, May RD, Till M, et al. (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48: 2610-2617.
8. Shen G, Li J, Ghetie M, et al. (1988) Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer 42: 792-797.
9. Irvin JD, Uckun FM. (1992) Pokeweed antiviral protein-ribosome inactivation and therapeutic applications. Pharmacol. Ther. 55: 279-302.
10. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63: 1424-1433.
11. Campana D, Janossy G, Bofill M, et al. (1985) Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J. Immunol. 134: 1524-1529.
12. Dörken B, Moldenhauer G, Schwartz R, Pezzutto A, Hammerling G. (1983) B cell differentiation antigens identified by monoclonal antibodies (HD6, HD28, HD37, HD39). Immunobiology 165: 253-254.
13. Ghetie V, Thorpe PE, Ghetie M, Knowles P, Uhr JW, Vitetta ES. (1991) The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J. Immunol. Methods 142: 223-230.
14. Ghetie V, Ghetie M, Uhr JW, Vitetta ES. (1988) Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. J. Immunol. Methods 112: 267-277.
15. 2, and B chains and characterization of their toxicity. J. Biol. Chem. 261: 5314-5319.
16. Knowles PP, Thorpe PE. (1987) Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem. 160: 440-443.
17. Endo Y, Mitsui K, Motizuki M, Tsurugi K. (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 262: 5908-5912.
18. Bjorn MJ, Ring D, Frankel A. (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 45: 1214-1221.
19. Weiner LM, O'Dwyer J, Kitson J, et al. (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 49: 4062-4067.
20. Vanhorssen PJ, Preijers FWMB, Vanoosterhout YVJM, Dewitte T. (1996) Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in Nude mice. Int. J. Cancer 68: 378-383.
21. Blakely DC, Watson GJ, Knowles PP, Thorpe PE. (1987) Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 47: 947-952.
22. Nadler LM, Anderson KC, Marti G, et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 131: 244-250.
23. Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM. (1991) Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. Methods 136: 221-237.
24. Uckun FM. (1993) Immunotoxins for the treatment of leukemia. Br. J. Haematol. 85: 435-438.
25. Mansfield E, Pastan I, FitzGerald DJ. (1996) Characterization of RFB4 - Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug. Chem. 7: 557-563.
26. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. (1990) Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer 45: 481-485.
27. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83: 1329-1336.
28. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. (1991) Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphomas grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res. 51: 5876-5880.
29. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. (1992) The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80: 2315-2320.
30. Ghetie M-A, Tucker K, Richardson J, Uhr JW, Vitetta ES. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84: 702-707.
31. Ghetie MA, Podar EM, Gordon BE, Pantazis P, Uhr JW, Vitetta ES. (1996) Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer 67: 1-4.
32. Shah SA, Halloran PM, Ferris CA, et al. (1993) Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 53: 1360-1367.
33. O'Connor R, Liu C, Ferris CA, et al. (1995) Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 86: 4286-4294.
34. Uckun FM, Finnegan D, Gunther R, et al. (1994) In vivo efficacy of B-43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin against BCL-1 murine B-cell leukemia. Blood 84: 702-707.
35. + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 79: 3116-3129.
36. Flavell DJ, Flavell SU, Boehm DA, et al. (1995) Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br. J. Cancer 72: 1373-1379.
37. Vitetta ES, Stone M, Amlot P, et al. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51: 4052-4058.
38. Amlot PL, Stone MJ, Cunningham D, et al. (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82: 2624-2633.
39. Sausville EA, Headlee D, Stetler-Stevenson M, et al. (1995) Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85: 3457-3465.
40. Stone MJ, Sausville EA, Fay JW, et al. (1996) A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88: 1188-1197.
41. Conry RM, Khazaeli MB, Saleh MN, et al. (1995) Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration. J. Immunother. 18: 231-241.
42. Kwak LW, Grossbard ML, Urba WJ. (1995) Clinical applications of monoclonal antibodies in cancer. In: De Vita VT, Jr, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer, J.B. Lippincott, Philadelphia, pp. 553-565.
43. Uckun FM. (1995) B43-pokeweed antiviral protein (B43-PAP) immunotoxin [abstract]. Fourth International Symposium on Immunotoxins, Myrtle Beach, S. Carolina, p. 162.